A Method to Simplify Patient-Specific QA of Single Isocenter Multiple Met SRS Plans

Abstract

<h3>Purpose/Objective(s)</h3> Pre-treatment quality assurance of single isocenter multi-met stereotactic radiosurgery (SRS) plans is standardly performed by acquiring a dose measurement using a detector array or ion chamber and film. The major efficiency issue with QA of these plans is how many, and which of the multiple metastases (mets) should be measured. The purpose of this study was to develop a workflow using an independent 3D dose calculation (DC) and trajectory log (TL) QA software to efficiently determine which of the brain mets should be further evaluated by measurement. <h3>Materials/Methods</h3> 30 single isocenter multiple metastasis patient SRS plans with a total of 82 mets were retrospectively studied. The clinical SRS plans were generated with an automated dynamic conformal arc SRS planning system (TPS). All plans were sent to the DC software for calculation. The gamma analysis (3%, 1 mm), percent difference between TPS and DC calculated mean and max dose to PTV, and the dose difference of the centroid point of each PTV was recorded. All plans were delivered to a high-resolution diode array designed for SRS and measurements were used to perform a gamma analysis (3%, 1 mm). In addition, the trajectory logs of the QA delivery were used to calculate 3D dose distributions and the same metrics acquired from the DC software were calculated and recorded. Pearson correlation between DC and TL calculated metrics was calculated. <h3>Results</h3> The results of the dosimetric metrics calculated by the DC and TL software are presented in Table 1. Overall agreement between DC and TPS was excellent, with all mean percent differences within 1.1% and mean gamma pass rates greater than 99%. Furthermore, dosimetric metrics calculated by DC and TL were highly correlated, with the correlation coefficients for all metrics at least 0.96, which suggests DC results can be used to predict TL QA results. To use DC to screen which PTVs should be further evaluated, an action level was set such that if any metric fell outside the 95% confidence interval (mean + 1.96 × SD), a QA measurement would be performed. For all metrics, a ±5% action level was calculated to cover the 95% confidence interval. DC results for 6 PTVs exceeded the action level. Of these plans, the measured patient specific QA passed for all plans. While all measured QA passed, DC and TL QA appeared to be more sensitive than the diode array measurement in identifying potential plan quality issues. <h3>Conclusion</h3> An efficient workflow for patient specific QA of single isocenter multiple met SRS plans was developed. An independent 3D dose calculation is used to calculate agreement of dosimetry metrics compared to the TPS. If the percent difference of a metric for a PTV exceeds a 5% action level, it is selected for further QA using a dose measurement.